Bloomberg Law®, an integrated legal research and business intelligence solution, combines trusted news and analysis with cutting-edge technology to provide legal professionals tools to be...
Merck Eprova AG v. Gnosis S.p.A.,
S.D.N.Y., No. 1:07-cv-05898, 9/30/12
A maker of nutrition supplements made literally false statements in its product literature by claiming to make a pure isomer product when in fact it was selling a less beneficial and less expensive to make mixture, the U.S. District Court for the Southern District of New York ruled Sept. 30 (Merck Eprova AG v. Gnosis S.p.A., S.D.N.Y., No. 1:07-cv-05898, 9/30/12).
The court further determined that the defendant's corporate witnesses lied in court, justifying an enhanced award, attorneys' fees, and additional expenses that will spent on a corrective advertising campaign.
The court's enhanced award totaled over $525,000, three times the sales of the defendant's product during the period it was falsely advertised.
Merck Eprova AG and Gnosis S.p.A. are competitors that make raw dietary ingredients used in the production of nutrition supplements. Merck sells the “6S Isomer” product Metafolin, which is essentially pure. Gnosis sells Extrafolate, a “6R,S Mixture Product,” which is not.
Merck sued Gnosis in the New York federal court claiming federal and state false advertising and unfair competition charges. The charges stemmed from Gnosis's marketing materials indicating that Extrafolate was a pure S-isomer product.
First, the evidence showed that Gnosis's product specification sheet for its 6R,S Mixture Product, distributed at a trade show in Anaheim, Calif., and distributed to customers thereafter, used the chemical name and the Chemical Abstracts Services (CAS) registry number for the pure 6S isomer.
Product specification sheets are “commercial advertising,” the court said, the chemical name was literally false, and it was material because “the very nature of what a manufacturer is selling is material.”
A false advertising claim under 15 U.S.C. §1125(a)(1)(B) also requires a showing of actual deception, but, citing Time Warner Cable Inc. v. DirecTV Inc., 497 F.3d 144, 153 83 USPQ2d 1897 (2d Cir. 2007), the court said, “When a plaintiff demonstrates the literal falsity of an advertisement, consumer deception is presumed.”
The court thus concluded that the product specification sheets violated the Lanham Act.
The court acknowledged a lively debate in the stereochemistry industry over nomenclature, describing testimony by one of Gnosis's witnesses as “metaphysical” and “at times fascinating.” However, the court said that while the debate is proper “at conferences and in scientific papers,” those arguments and documents could not possibly be construed as advertising.
Further, Gnosis had not consulted this witness prior to creating the brochures and other documents, the court noted. The witness's testimony was thus “an after-the-fact rationalization for a scheme that was animated by purely commercial, and not scientific, motives,” the court declared.
Finally, the court looked at the descriptions of the 6R,S Mixture Product in the same literature and concluded that those descriptions, while true of pure product, were stated as being true for the mixture.
Again, the court said, “though a claim of deceptive advertising generally requires extrinsic evidence of consumer confusion to prevail, a presumption of deceit arises where a defendant is shown to have intended to mislead consumers and acted egregiously to that end.”
The court did, however, find contributory false advertising in that Gnosis caused its Extrafolate distributor to falsely advertise when the distributor used Gnosis's materials.
Merck's state law claims--deceptive trade practices and false advertising under Sections 349 and 350, respectively, of the New York General Business Law--were dismissed, though. The state claims require a showing of harm to the public, the court said. “Instead, Merck's allegations focus almost entirely on losses suffered by Merck itself, not to the eventual--and theoretical--harm suffered by the public at large.”
The Lanham Act, at 15 U.S.C. §1117(a), allows an award of (1) defendant's profits, (2) any damages sustained by the plaintiff, and (3) the costs of the action.
The court awarded lost profits of over $175,000, equal to the entire amount of revenues Gnosis realized for sales of Extrafolate from 2006 to the point in 2009 when it corrected its false materials. The court rejected Gnosis's estimates of its costs “given the Court's findings about the credibility of Gnosis's witnesses.”
Though Section 1117(a)(3) allows trebling the award as an enhancement of damages only, it also allows the court to enhance the award “for such sum as the court shall find to be just, according to the circumstances of the case.” Indeed, this court trebled the award on those grounds, to reflect Gnosis's ill-gotten increase in market share, which extended beyond the period in which Gnosis falsely advertised.
“Though an award of three times profit is an imprecise measure of compensation, the impossibility of gauging Merck's losses along with the undeniable existence of those losses makes it a proper, if crude, measure,” the court said. “Further, while an award under the Lanham Act must promote a compensatory and not punitive purpose, it is no small matter that Gnosis may be deterred from again engaging in such brazen behavior by being required to fully account for its actions.”
Prejudgment interest will also be added to the award, the court ruled.
The court did not go so far as Merck requested--a five-year ban--but it did “order Gnosis to engage in a campaign of corrective advertising.”
Finally, in light of “Gnosis's utter lack of respect for the judicial process,” the court awarded attorneys' fees as well.
Robert Elliot Hanlon of Alston & Bird, New York, represented Merck. William Donald Chapman of Julander, Brown, Bollard & Chapman, Irvine, Calif., represented Gnosis.
By Tony Dutra
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)